Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
A phase 1/2 trial of GIM-531 in melanoma, run by Georgiamune Inc, now recruiting.
Overview
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06425926 by Georgiamune Inc, with 117 participants planned, started 2024-05-09 and due to reach its primary completion in 2026-12. Interventions recorded: GIM-531 and Anti-PD-1 monoclonal antibody.
Setting
A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
Georgiamune Inc
Registry
Enrolled
117
Similar pages
not linked directly; found by shared links- TrialSafety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Shares Georgiamune and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Melanoma and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Melanoma and the tag pipeline.
- TrialAMT-253 in Patients With Advanced Solid Tumours
Shares Melanoma and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Melanoma and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma and the tag pipeline.